Add-on aliskiren treatment can decrease blood pressure but requires attention to risks of renal impairment and hyperkalemia Chikushi Anti-Hypertension Trial-Rasilez ® (CHAT-Ras).

Conclusion: While add-on AL treatment achieved a favorable and sustained decrease of BP in this study, caution is necessary with regard to elevation of potassium levels and renal impairment. PMID: 32037898 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32037898?dopt=Abstract

Source: Clinical and Experimental Hypertension - February 7, 2020 Category: Cardiology Authors: Okamura K, Takamiya Y, Mori K, Shirai K, Urata H Tags: Clin Exp Hypertens Source Type: research